

ECM

L'evento è stato accreditato dal Provider PLS Educational (3516-171808Ed. 1) per la professione del Medico Chirurgo nelle discipline di Gastroenterologia, Chirurgia Generale, Medicina Interna, Pediatria, Pediatria di Libera Scelta. L'evento prevede l'assegnazione di 10 crediti formativi.

SCIENTIFIC SECRETARIAT

Ambrogio Orlando
Claudio Romano

FACULTY

Marina Aloï (Rome, Italy)
Alessandro Armuzzi (Rome, Italy)
Livia Biancone (Rome, Italy)
Calogero Cammà (Palermo, Italy)
Maria Cappello (Palermo, Italy)
Fabiana Castiglione (Naples, Italy)
Michele Citrano (Palermo, Italy)
Mario Cottone (Palermo, Italy)
Antonio Craxì (Palermo, Italy)
Valeria Criscuoli (Palermo, Italy)
Walter Fries (Messina, Italy)
Paolo Gionchetti (Bologna, Italy)
David Laharie (Bordeaux, France)
Paolo Lionetti (Florence, Italy)
Fabio Salvatore Macaluso (Trapani, Italy)
Salvatore Madonia (Palermo, Italy)
Erasmus Miele (Naples, Italy)
Filippo Mocciaro (Palermo, Italy)
Giuseppe Navarra (Messina, Italy)
Ambrogio Orlando (Palermo, Italy)
Emanuele Orlando (Palermo, Italy)
Claudio Papi (Rome, Italy)
Gilberto Poggioli (Bologna, Italy)
Sara Renna (Palermo, Italy)
Claudio Romano (Messina, Italy)
Chiara Sapienza (Catania, Italy)
Gaspere Solina (Palermo, Italy)
Maurizio Vecchi (Milan, Italy)
Francesco Vitale (Palermo, Italy)



www.maki-adv.it

SEDE

Grand Hotel Piazza Borsa
Via dei Cartari, 18 - 90133 Palermo

SEGRETERIA ORGANIZZATIVA



PLS Educational Srl
Via della Mattonaia, 17 - 50121 Firenze
Tel. 055 2462241 - Fax 055 2462270
E-mail: lisa.peruzzi@promoleader.com
www.promoleader.com

THANKS TO ALL THE SPONSORS
FOR THEIR EDUCATIONAL
AND NO-CONDITIONING CONTRIBUTION
FOR THE CONGRESS REALIZATION



II Congress Safety of immunosuppressive treatment in the management of Inflammatory Bowel disease

Grand Hotel Piazza Borsa **Palermo**
9-10 dicembre 2016

Venerdì
9 dicembre 2016

- 14.15-14.30** Greetings from the General Manager of "VILLA SOFIA-CERVELLO" Hospital
Ing. G. Venuti
- 14.30-14.35** Introduction
*M. Cottone
A. Orlando
C. Romano*

SESSION I

Chairmen: M. Cottone, A. Orlando

- 14.35-15.00** Network on biologics in Sicily, advantages and limitations: up to date
M. Cottone
- 15.00-15.15** Discussion
- 15.15- 15.40** AIFA project on the safety of immunosuppressive treatment: final results
A. Orlando
- 15.40-16.00** Discussion

SESSION II

Chairman: A. Craxi

- 16.00-16.15** Clinical case
C. Sapienza
- 16.15-16.40** Hepatitis B and C virus infection and Immunosuppressive therapy in patients with IBD in children and adults
S. Madonia
- 16.40-17.05** Is it CMV infection a contraindication to immunosuppressive and biological therapy in children and adults?
V. Criscuoli
- 17.05-17.30** Immunosuppressive (thiopurines, methotrexate...) treatment related infections in adults
W. Fries
- 17.30-17.55** Immunosuppressive (thiopurines, methotrexate...) treatment related infections in children
C. Romano
- 17.55-18.20** Biological treatment related infections in children and adults
S. Renna
- 18.20-18.45** Discussion

Sabato
10 dicembre 2016

SESSION III

Chairmen: E. Miele, M. Vecchi

- 08.30-08.45** Clinical case
E. Orlando
- 08.45-09.10** Risk of Cancer in IBD patients treated with biologics
L. Biancone
- 09.10-09.40** Risk of Cancer in IBD patients treated with thiopurines and methotrexate and management in patients with Cancer history: updating
D. Laharie
- 09.40-10.10** Which is the safety profile of new biological drugs?
F. Mocciano
- 10.10-10.45** Discussion
- 10.45-11.00** COFFEE BREAK

SESSION IV

Chairmen: M. Cappello, P. Lionetti

- 11.00-11.15** Clinical case
M. Citrano
- 11.15-11.40** Biologics in early onset Inflammatory Bowel Disease: indications and treatment related safety
M. Aloï
- 11.40-12.05** Biologics in elderly: indications and treatment related safety
M. Cottone
- 12.05-12.20** Discussion

- 12.20-12.45** Immunosuppressive therapy in pregnancy and lactation in IBD patients
F. Castiglione
- 12.45-13.10** Role of vaccines in patients treated with immunosuppressants and biologics: updating
F. Vitale
- 13.10 - 13.30** Paradoxical reactions to biologics in patients with IBD
A. Armuzzi
- 13.30-13.50** Discussion
- 13.50-15.00** LUNCH

SESSION V

Chairmen: C. Cammà, G. Navarra

- 15.00-15.15** Clinical Case
F.S. Macaluso
- 15.15-15.45** Tandem Talk: Biological treatment increases infectious complications related to surgery in Ulcerative Colitis?
P. Gionchetti, G. Poggioli
- 15.45-16.05** Discussion
- 16.05-16.35** Tandem Talk: Biological treatment increases infectious complications related to surgery in Crohn's Disease?
C. Papi, G. Solina
- 16.35-16.50** Discussion
- 16.50-17.00** Closing remarks
A. Orlando, C. Romano
- 17.00-17.20** CME completion



II Congress

Safety of immunosuppressive treatment in the management of Inflammatory Bowel disease

Palermo, 9-10 dicembre 2016

This is the second edition of the congress held in December 2014 on the safety of the immunosuppressive and biologics treatment in Inflammatory Bowel Disease (IBD). In this edition the focus will also be given within pediatric and surgery fields. Infections and malignancies are the major issues for clinicians in the management of patients with IBD because of concerns about the safety of drugs currently used in treatment, including immunosuppressive agents and tumor necrosis factor (TNF) antagonists. Infections are strongly associated with IBD both in their etiopathogenesis and in their clinical course. A number of viral infections, tuberculosis and other therapy-related infections create challenges for the successful management of intestinal disease with immunosuppressive agents or TNF antagonists. Recently published guidelines offer a strong support to deal with these issues. Major concern about IBD patients with malignancies is related to the risk of maintaining immunosuppressant or anti-TNF therapy also after the diagnosis of malignancy. Further research is required to optimize strategies for IBD patients with malignancies. At the moment, all therapeutic choice is made on an individual basis, with an integrative multidisciplinary approach. The congress will develop the best strategies for managing these issues and all the sessions will be preceded by a clinical case coherent with the topics. Finally, will present the results of the network on the treatment with biologics of the IBD in Sicily and the final results of AIFA project on the safety of immunosuppressive treatment in IBD in our center.